Related Experiment Video
Updated: Jan 6, 2026

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis
Published on: June 18, 2020
Monoclonal gammopathy associates with kidney failure in ANCA-associated vasculitis
Poemlarp Mekraksakit1, Maria J Vargas-Brochero1, Ilario Russo2
1Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Background:
Up to 20% of patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and kidney involvement progress to end-stage kidney disease (ESKD) despite therapy. The role of monoclonal gammopathy (MG) in disease progression in patients with AAV is not well understood.
Methods:
We conducted a retrospective study to identify patients diagnosed with AAV and renal involvement who had undergone monoclonal protein testing between November 1999 and December 2023. A total of 167 patients were included in the renal survival analysis and were categorized into monoclonal positive (n = 34) and monoclonal negative (n = 133) groups. For the mortality analysis, we expanded the cohort to include an additional 26 patients who were dialysis-dependent at baseline and remained on dialysis throughout follow-up, resulting in a total of 193 patients. We performed multivariate Cox analysis to identify predictors of adverse renal events [>40% decline in estimated glomerular filtration rate (eGFR) or ESKD (eGFR <15 mL/min/1.73 m², need for dialysis or transplantation)] and mortality.
Results:
Median age of the cohort was 68 (58.5-74.5) years, with 50.8% males, 65.8% MPO positive, and 64.6% receiving rituximab as induction therapy. After adjusting for baseline proteinuria, sclerotic Berden class and induction therapy, MG was associated with adverse renal events [hazard ratio (HR) 3.29 (95% confidence interval 1.12-9.68), P = .03]. MG at baseline was not associated with mortality [HR 1.65 (0.87-3.12), P = .12], however patients with persistent MG at 6 months had higher mortality compared with those without MG or those whose MG was not sustained [HR 3.95 (1.10-14.21), P = .035].
Conclusions:
Patients with AAV and renal involvement who have MG are at significantly increased risk of adverse renal events even after adjusting for factors such as eGFR and degree of chronicity (known predictors of poor renal outcome). The exact mechanism by which MG portends poor outcomes is poorly understood, and additional research is required.
Related Concept Videos
Acute Kidney Injury II: Pathophysiology
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury III: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury I: Introduction

